An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10 mg in Subjects With MS.
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2013
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms STEADY
- 28 May 2013 Data will be presented at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), according to an Acorda Therapeutics media release.
- 13 Mar 2013 Data was presented at the 65th American Academy of Neurology Annual Meeting (AAN-2013; P04.103), according to an Acorda Therapeutics media release.
- 30 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.